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The detection of somatic single nucleotide variants is a crucial component to the 
characterization of the cancer genome. Mutation calling algorithms thus far have 
focused on comparing the normal and tumor genomes from the same individual. In 
recent years, it has become routine for projects like The Cancer Genome Atlas (TCGA) 
to also sequence the tumor RNA. Here we present RADIA (RNA and DNA Integrated 
Analysis), a method that combines the patient-matched normal and tumor DNA with the 
tumor RNA to detect somatic mutations. The inclusion of the RNA increases the power 
to detect somatic mutations, especially at low DNA allelic frequencies. By integrating the 
DNA and RNA, we are able to rescue back calls that would be missed by traditional 
mutation calling algorithms that only examine the DNA. 
RADIA was developed for the identification of somatic mutations using both DNA 
and RNA from the same individual. We demonstrate high sensitivity (84%) and very 
high specificity (98% and 99%) in real data from endometrial carcinoma and lung 
adenocarcinoma from TCGA. Mutations with both high DNA and RNA read support 
have the highest validation rate of over 99%. We also introduce a simulation package 
that spikes in artificial mutations to real data, rather than simulating sequencing data 
from a reference genome. We evaluate sensitivity on the simulation data and 
demonstrate our ability to rescue back calls at low DNA allelic frequencies by including 
the RNA. Finally, we highlight mutations in important cancer genes that were rescued 
back due to the incorporation of the RNA. 
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Much of our current understanding of cancer has come from investigating how normal 
cells are transformed into cancerous cells through the stepwise acquisition of somatic 
genomic abnormalities.  These events include point mutations, insertions and deletions 
(INDELs), chromosomal rearrangements, and changes to the copy number of segments 
of DNA.  Transforming a normal human cell into a malignant, immortal cancer cell line 
requires an estimated five to seven genetic alterations in key genes and pathways 
(Hahn et al., 1999; Hanahan and Weinberg, 2000).  Not surprisingly, much research has 
been devoted to determining how cancer cells are able to acquire their abilities through 
the accumulation of somatic mutations. 
 
The Cancer Genome Atlas (TCGA) project has produced exome-wide data from 
thousands of tumors and patient-matched normal tissues.  With the development of 
RNA Sequencing (RNA-Seq), TCGA began providing an additional high-throughput 
tumor sequence dataset.  These three datasets consisting of tumor and patient-matched 
normal DNA, and tumor RNA have become a new standard in cancer genomics.  RNA-
Seq enables one to investigate the consequences of genomic changes in the RNA 
transcripts they encode to better characterize 1) germline variants, 2) somatic 
mutations, and 3) variants in the RNA that are not found in the DNA that could be the 
result of RNA editing (Gott and Emeson, 2000). 
 
Over the next few years, many more whole-genome and exome-capture DNA and RNA-
Seq BAM (the binary version of Sequence Alignment/Map (Li et al., 2009)) files will 
become available.  TCGA has collected up to 10,000 tissue samples from more than 20 
types of cancer.  There is a clear need for an efficient method for the combined analysis 
of patient-matched tumor DNA, normal DNA, and tumor RNA.  Here we present a 
method called RADIA to identify and characterize alterations in cancer using DNA and 
RNA obtained by high-throughput sequencing data.  
 
Somatic mutation calling is traditionally performed on patient-matched pairs of tumor 
and normal genomes/exomes.  The ability to accurately detect somatic mutations is 
hindered by both biological and technical artifacts that make it difficult to obtain both 
high sensitivity and high specificity. Different mutation calling algorithms often disagree 
about putative mutations in the same source data, and frequently have discernible 
systematic differences due to the trade-off between sensitivity and specificity (Roberts 
et al., 2013).  This is especially true for somatic mutations with low variant allele 
frequencies (VAFs).  By creating an algorithm that utilizes both DNA and RNA, we have 
increased the power to detect somatic mutations, especially at low variant allele 
frequencies. 
 
RADIA combines patient-matched tumor and normal DNA with the tumor RNA to detect 
somatic mutations.  The DNA Only Method (DOM) (Fig. 1) uses just the tumor/normal 
pairs of DNA (ignoring the RNA), while the Triple BAM Method (TBM) (Fig. 1) uses all 
three datasets from the same patient to detect somatic mutations.  The mutations from 
the TBM are further categorized into 2 sub-groups:  RNA Confirmation and RNA Rescue 
calls (Supplementary Fig. 1).  RNA Confirmation calls are those that are made by both 
the DOM and the TBM due to the strong read support in both the DNA and RNA.  RNA 
Rescue calls are those that had very little DNA support, hence not called by the DOM, 
but strong RNA support, and thus called by the TBM.  RNA Rescue calls are typically 
missed by traditional methods that only interrogate the DNA.  
 
Fig. 1.  Overview of the RADIA work-flow for identifying somatic mutations.  The normal DNA, tumor DNA, 
and tumor RNA BAMs are processed in parallel and initial low-level variants are identified.  The variants are 
filtered by the DNA Only Method using the pairs of normal and tumor DNA and by the Triple BAM Method using 
all three datasets.  The calls from the two methods are merged and output in VCF format. 
We have applied RADIA to data derived from nearly 1,900 patients representing seven 
different cancer types from TCGA (Supplementary Table 1).  Overall, the RNA Rescue 
calls that are made possible by the incorporation of the RNA-Seq data provide a 2-7% 
increase in somatic mutation calls compared to the DOM (Supplementary Table 1).  
Many of these mutations were new discoveries that were not previously found by other 
mutation callers in TCGA.  Of these new discoveries, some mutations were found in 
well-known cancer genes that were heavily mutated in a specific cohort.  We also find 
mutations in new samples where the same gene has already been identified as 
harboring mutations in other samples from the cohort. When these RNA Rescue calls 
are added to the DNA Only calls, these genes achieve a statistically significant overall 
mutation rate for the cohort. 
 
Here we specifically focus on results from 177 Endometrial Carcinoma (Kandoth et al., 
2013) and 230 Lung Adenocarcinoma (submitted) patients from TCGA.  To demonstrate 
the increase in sensitivity from including the tumor RNA-Seq dataset, we simulated 
mutations by spiking them into real tumor DNA and tumor RNA using bamsurgeon 
(https://github.com/adamewing/bamsurgeon). We also evaluated sensitivity and 
specificity on real data using validation data that was generated by TCGA.  We highlight 
RNA Rescue mutations found by the TBM in tumor suppressor genes such as TP53, 
STK11, and CDKN2A in Lung Adenocarcinoma. 
 
<&&8,+=4*1&
 
RADIA operates on 2 or more BAM files, producing somatic mutation calls through a 
series of steps outlined in Fig. 1.  Each step in this process is described in detail, 
beginning with the initial selection of sites for further processing and ending with a 
description of filters used to eliminate false positives while maintaining true positive 
calls. 
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RADIA is typically run on 3 BAM (Li et al., 2009) files consisting of a pair of patient-
matched tumor and normal genomes and a tumor transcriptome and outputs germline 
(inherited) variants, Loss Of Heterozygosity (LOH) events, somatic Single Nucleotide 
Variants (SNVs), and RNA editing events.  Here we focus specifically on the detection 
of somatic SNVs with RADIA.  The DOM is run on the pairs of tumor and matched-
normal DNA while the TBM is applied to the DNA and RNA triplets.  After the DOM and 
TBM specific filters, the results are merged and run through a final read support filter 
(Fig. 1).  If RNA-Seq data is not available, RADIA can utilize paired tumor and normal 
DNA genomes using the DOM to detect germline variants, LOH events, and somatic 
SNVs. 
 
Internally, RADIA uses the samtools (Li et al., 2009) mpileup command (version 0.1.18) 
to examine the pileups of bases in each sample in parallel.  A heuristic algorithm 
determines the existence and type of variant at any given position based on the user-
configurable minimum thresholds for overall depth, variant depth, Base Alignment 
Quality (BAQ) (Li, 2011), and mapping quality.  Initially, RADIA requires a minimum 
overall depth of 4 bases, minimum variant depth of 2 bases, minimum phred BAQ of 10, 
and minimum phred mapping quality of 10.  These initial calls are lenient in coverage 
and provide a good baseline set of calls for further filtering. 
 
RADIA scans pileups of reads across the reference genome and outputs variants in 
Variant Call Format (VCF) (https://github.com/samtools/hts-specs).  For each position, 
summary information such as the overall depth, allele specific depth and frequency, 
average BAQ base quality, average mapping quality, and the fraction of reads on the 
plus strand are calculated for both the DNA and RNA.  All of this information is used 
during the filtering process. 
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Many current mutation calling algorithms have a pre-processing step to account for 
misaligned reads around INDELs.  This realignment step is computationally expensive 
and relies on accurately predicting the location of INDELs which in itself is not a trivial 
problem.  Base Alignment Quality (BAQ) is an alternative option for dealing with 
alignment ambiguity around INDELs.  It calculates the probability that a base has been 
misaligned and returns the minimum of the original base quality and the base alignment 
quality.  BAQ is run by default when executing a samtools mpileup command and has 
been shown to improve SNP calling accuracy (Li, 2011).  We use the extended version 
of BAQ (option –E) that is activated by default in the latest version of samtools (0.1.19) 
for increased sensitivity and slightly lower specificity (Li et al., 2009). 
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The 1000 Genomes Project coined the term “accessible genome” to be the part of the 
reference genome that is reliable for accurate variant calling after removing ambiguous 
or highly repetitive regions (1000 Genomes Project Consortium, 2010). Since the 
reference genome is incomplete, repetitive in places, and does not represent human 
genetic variation comprehensively, reads often get mapped incorrectly in locations 
outside the accessible genome (inaccessible sites), leading to false positive variant 
calls.  Over 97% of inaccessible sites are due to high copy repeats or segmental 
duplications. In the pilot, the 1000 Genomes Project determined that 85% of the 
reference sequence and 93% of the coding region was accessible. Due to longer read 
lengths (75-100 bp) and improvements to both paired end protocols and sequence 
alignment algorithms, the accessible genome has increased to 94% of the reference 
and 98% of the coding region in Phase I (1000 Genomes Project Consortium, 2012).  
We filter variants that are not in the accessible genome using the 1000 Genomes Phase 
I mapping quality and depth blacklists (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phas 
e1/analysis_results/supporting/accessible_genome_masks/). 
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It has recently been shown that variant allele reads that occur exclusively on one strand 
are largely associated with false positive calls (Larson et al., 2012).  In order to account 
for this technical artifact, we filter based on the variant allele strand bias.  If we have at 
least 4 total reads supporting the variant allele, then we apply the strand bias filter if 
more than 90% of the reads are on the forward strand or more than 90% are on the 
reverse strand. 
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RADIA can be executed on patient-matched pairs of tumor and normal DNA samples 
using the DOM to identify germline variants and somatic mutations.  We first compare 
the matched normal DNA to the human reference genome.  We require the normal DNA 
to pass the mpileup support filters described in Table 1 for all germline variants. 
 
If no germline variant is found, we compare the tumor DNA to the matched normal DNA 
and the reference to search for somatic mutations. We require the normal DNA and 
tumor DNA to pass the mpileup support filters shown in Table 1 for all somatic variants.  
To ensure that we have the power to detect a possible germline variant at this site, we 
require that the normal DNA depth is 10 or more. 
 
Table 1.  DNA Only Method mpileup support filters.  The germline variants and somatic mutations 
from the DOM are filtered according to the parameters described here.  The minimum average alternative 
read BAQ filter uses the phred scale.  The maximum other percent restricts the percentage of reads that 
are allowed to support an additional alternative allele. 
 
We use the Triple BAM Method to augment our somatic mutation calls using both the 
pairs of DNA and the RNA-Seq data.  The normal DNA, tumor DNA, and tumor RNA 
must pass the mpileup support filters shown in Table 2 for all somatic variants.  We 
Filter Germline 
Normal DNA 
Somatic 
      Normal DNA                   Tumor DNA 
Min Total Depth 10 10 10 
Min Alt. Depth 4 NA 4 
Min Alt. Percent 10% NA 10% 
Min Avg. Alt. BAQ 20 NA 20 
Max Alt. Strand Bias 90% NA 90% 
Max Alt. Percent NA 2% NA 
Max Other Percent 2% 2% 2% 
require at least one read with a minimum BAQ phred score of 15 in the tumor DNA to 
make a call.  To rule out possible germline variants, we again require that the normal 
DNA depth is 10 or more.  In addition, we filter out calls that overlap with dbSNP.  We 
found that many false positive variants overlapped with earlier versions of dbSNP.  
These variants were due to technical artifacts and were removed from subsequent 
versions of dbSNP (Musumeci et al., 2010).  Therefore, we filter out all variants that 
overlap with dbSNP versions 130, 132 or 135 (ftp://ftp.ncbi.nih.gov/snp/).  The TBM 
calls are subjected to further filtering procedures as shown in Fig. 1 and described 
below. 
 
Filter Somatic 
      Normal DNA                  Tumor DNA                   Tumor RNA 
Min Total Depth 10 1 10 
Min Alt. Depth NA 1 4 
Min Alt. Percent NA NA 10% 
Min Avg. Alt. BAQ NA 15 15 
Max Alt. Strand Bias NA 90% 90% 
Max Alt. Percent 10% NA NA 
Max Other Percent 10% 10% 2% 
Table 2.  Triple BAM mpileup support filters.  The somatic mutations from the TBM are filtered 
according to the parameters shown here. 
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We noticed that many of our TBM mutations overlapped with predicted pseudogenes.  
Although expressed pseudogenes have recently been reported to be significant 
contributors to the transcriptional landscape and shown to play a role in cancer 
progression (Kalyana-Sundaram et al., 2012), mutations that overlap with predicted 
pseudogenes have a high false positive rate.  Sequence similarity of pseudogene 
copies to their parent genes leads to uncertainty in alignment within these regions.  
Because of these technical artifacts, we remove TBM mutations that overlap with 
pseudogenes (Baertsch et al., 2008; Harrow et al., 2012). 
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We remove TBM mutation calls that overlap with families of genes that have high 
sequence similarity.  Some examples of these gene families are Major Histocompatibili-
ty Complexes (MHCs), Human Leukocyte Antigens (HLAs), Ribosomal Proteins (RPLs), 
immunoglobulins and zinc fingers.  While mutations in these genes may exist, special 
processing would be needed to distinguish them from false positive calls due to 
misaligned reads. 
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False positive calls are sometimes associated with misaligned reads where the 
alternative allele is consistently within a certain distance from the start or end of the 
read.  The positional bias filter is applied when 95% or more of the reads that have an 
alternative allele are such that the alternate allele falls in the first third or last third of the 
read. 
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We observed multiple instances where RNA-Seq reads appeared to be incorrectly 
mapped due to the added difficulties in aligning RNA-Seq data, such as dealing with 
hard to identify splice junctions and multiple gene isoforms.  To guarantee that the RNA-
Seq reads that support a variant do not map better to another location in the genome, 
we created a BLAT filter.  All of the RNA-Seq reads that support a variant were 
extracted from the BAM file and aligned to the human genome using BLAT (Kent, 2002).  
If the read mapped to another location with a better score, then the read was rejected.  
After using BLAT on each read, we again require that there are 4 valid reads that 
support the variant and that 10% or more of the reads support the variant. 
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We merge the calls from the DOM and the TBM and apply one final filter.  We require 
that each somatic mutation be supported by at least 4 “perfect” reads.  We define a 
perfect read as follows: 
 
1. Minimum mapping quality of read is 10 
2. Minimum base quality of alternative allele in read is 10 
3. Minimum base qualities of the 5 bases up- and down-stream of the alternative 
base are 10 
4. Read is properly paired 
5. Read has less than 4 mismatches across its entirety when compared to the 
reference 
6. Read doesnʼt require an insertion or deletion to be mapped 
 
After determining the number of perfect reads that support the reference and the 
alternative at a coordinate, we re-apply the strand bias filter to guarantee that no more 
than 90% of the total perfect reads are from one strand. 
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In order to evaluate sensitivity and demonstrate the increase in power from including the 
RNA sequence data, we simulated somatic mutation calls starting from real data.  We 
spiked mutations into a pair of breast cancer tumor DNA and tumor RNA samples using 
bamsurgeon (https://github.com/adamewing/bamsurgeon), a tool we developed to 
generate simulation data that closely mimics actual experimental data from high-
throughput sequencing datasets.  Bamsurgeon first determines the loci that have an 
appropriate DNA and RNA depth to spike in mutations.  It then extracts the reads at the 
loci, adjusts the VAF according to the user-defined VAF distribution, and then re-maps 
the reads (Supplementary Figure 2).  This simulation strategy is more sophisticated than 
simply generating simulated reads from a reference genome, as it retains the biological 
and technical artifacts that are inherently present in next generation sequencing data. 
 
We performed two spike-in experiments:  one varying the DNA VAF while holding the 
RNA VAF constant, and inversely, varying the RNA VAF while holding the DNA VAF 
Fig. 2 Sensitivity of RADIA on simulated data where artificial mutations were spiked into the tumor DNA 
and RNA of a breast cancer patient using bamsurgeon.  (A) Mutations were spiked into the DNA at VAFs from 
1-50%.  Mutations in the RNA were spiked in at a constant 25%.  The overall sensitivity of RADIA was 86%. RNA 
Rescue calls from the Triple BAM method detected the mutations that had a DNA VAF < 10%.  (B) Mutations were 
spiked into the DNA at 10% or less and into the RNA from 1-50%.  Most of the DOM calls are filtered due to the 
low DNA allelic frequency.  The calls that have adequate RNA read support are rescued back at these low DNA 
allelic frequencies. 
 
constant.  To evaluate the sensitivity of RADIA, we spiked in 1,594 mutations to the 
tumor DNA sequence with a variant allele frequency ranging from 1-50% and to the 
tumor RNA sequence at a constant frequency of 25%.  We used the original tumor DNA 
in place of the matched-normal and made mutation calls with RADIA.   
 
The overall sensitivity rate averaged across all VAFs is 85% consisting of 1,351 out of 
1,594 spiked in mutations (Fig. 2A).  Of the 243 calls that were filtered out, over 50% 
are removed because they failed to meet the minimum variant allele frequency, more 
than 20% land in blacklist regions that the method ignores, and nearly 20% are 
discarded due to the BLAT filter.  The number of mutations that are rejected by the full 
list of filters can be found in Supplementary Figure 3. 
 
To demonstrate the ability of the TBM to rescue back calls at low DNA VAFs, we spiked 
in 1,761 mutations to the tumor RNA sequence with a variant allele frequency ranging 
from 1-50% and to the tumor DNA sequence at 10% or less.  Most of the mutations by 
the DOM are filtered out due to the low allelic frequency in the DNA (Supplementary 
Figure 4).  For the calls that have sufficient read support in the RNA, these low DNA 
VAFs are rescued back (Fig. 2B). 
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We made somatic mutation calls on 177 non-hypermutated TCGA endometrial 
carcinoma samples (Kandoth et al., 2013).  For these 177 samples, there exists 
validation data from the tumor and matched-normal DNA samples.  We utilized a 
validation criterion similar to the one used by the TCGA Endometrial Working Group to 
validate the multi-center network mutation calls (Kandoth et al., 2013).  For each 
somatic mutation, we queried the patient-matched tumor and normal validation data.  
We required at least 10 reads in both the tumor and normal data in order to determine if 
a call validated, otherwise we classified it as ambiguous.  If the variant was present at 
low levels in both datasets, we also classified it as ambiguous.  Otherwise, we 
determined whether a mutation validated as germline/LOH, somatic, or neither 
according to Table 3.  In addition, any RNA Rescue call in the “Not Validated” group that 
overlapped with COSMIC was considered as validated. 
 
Normal VAF Tumor VAF 
 0% < 8% ! 8%, < 20% ! 20% 
= 0% Not Validated Somatic Low Somatic Med Somatic High 
< 3% Not Validated Ambiguous Somatic Med Somatic High 
! 3% Germline/LOH Germline/LOH Germline/LOH Germline/LOH 
Table 3.  Validation strategy in endometrial data.   Validation BAMs were used to determine the 
validation status for somatic mutations as shown here.  A mutation is considered validated in the Somatic 
Low, Med, or High groups (blue) and not validated in the “Not Validated” (green) and Germline/LOH 
groups (red). 
 
We made a total of 27,900 somatic mutation calls over 177 endometrial samples, of 
which 27,390 and 6,325 calls were made by the DOM and TBM respectively.  Of the 
6,325 TBM calls, there were 5,815 RNA Confirmation calls that were made by both the 
DOM and TBM signifying high DNA and RNA support, and importantly, a total of 510 
RNA Rescue calls that were missed by the DOM. 
 
Using the validation strategy described above, we demonstrate that the overall 
specificity for RADIA is 98% (Fig. 3A).  Due to lack of coverage or uncertainty in the 
Fig 3. Specificity and sensitivity of RADIA on 177 non-hypermutated endometrial carcinoma patients.  
Mutations are considered validated in the Somatic Low, Med, or High groups (blue), not validated in the “Not 
Validated” (green) and Germline/LOH (red) groups, and Ambiguous (orange) when there was low read depth (<10 
reads) or ambiguity in the validation data. (A) An overall specificity of 98% was demonstrated.  RNA Confirmation 
calls with strong DNA and RNA support validated over 99%.  RNA Rescue calls validated at 81%.  (B) The union 
of all calls submitted by the TCGA network that validated as somatic was considered as the truth set.  RADIA 
demonstrated an overall sensitivity rate of 84%.  Of the calls that were missed, 33% occur at low variant allele 
frequencies and 23% occur in blacklist regions that are ignored. 
tumor and normal validation BAMs, a total of 1,825 calls were considered to be 
ambiguous.  25,520 mutations validated as somatic, 271 validated as germline/LOH 
variants and 284 were not validated.  The specificity of calls made by the DOM and the 
TBM were 98% and 98.5% respectively.  Over 99% of the calls that were made by both 
the DOM and the TBM were validated.  There were 510 RNA Rescue calls that were 
made only by the TBM, and even though most of these calls were not targeted for 
validation, 81% of them validated as somatic.  175 of the 210 (83%) RNA Rescue calls 
validated using the validation BAMs while the remaining 35 (17%) were validated by 
COSMIC. 
 
In order to measure the sensitivity of RADIA, we considered the union of all calls 
submitted by the TCGA network from the Broad Institute and The Genome Institute at 
Washington University that validated as somatic as our truth set.  There were 30,239 
calls that validated as somatic from the TCGA network.  We compared our somatic 
mutation calls to this truth set and demonstrated overall sensitivity of 84% (Fig. 3B, 
Supplementary Figure 5).  Of the 4,751 calls that were missed, 1,539 (33%) were 
filtered by RADIA because they had a variant allele frequency less than 8% 
(Supplementary Figure 6).  In addition, 1,072 (23%) landed in blacklist regions that were 
not considered (Supplementary Figure 6).  
 
Finally, RADIA somatic mutation calls were analyzed during the course of our 
participation in the TCGA Lung Adenocarcinoma Working Group (submitted).  Validation 
was performed by the Broad Institute on 74 genes of interest along with an additional 
1,150 somatic SNVs.  Validation was attempted on 2,404 RADIA calls and 2,395 
(99.63%) were verified.  From the DOM, 2,336 of the 2,345 calls (99.62%) validated.  
Importantly, 469/469 (100%) of the TBM calls consisting of 410 RNA Confirmation and 
59 RNA Rescue calls were validated. 
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Mutations in the tumor suppressor gene TP53 are common in the majority of human 
cancers.  Most of the mutations occur in the DNA-binding domain (DBD) and are 
considered change-of-function mutations that alter activity of TP53, sometimes acting in 
a dominant negative manner to sequester wildtype tp53 protein in trans (Friedman et al., 
1993).  As such, many p53 mutant proteins endow cells with oncogenic characteristics 
by promoting cell proliferation, survival, and metastasis (Muller and Vousden, 2012). 
 
We ran RADIA on 230 TCGA Lung Adenocarcinoma triplets (submitted) and discovered 
two non-synonymous TP53 mutations that were below the detection threshold for other 
analysis procedures used by the TCGA network working group (Table 4).  Both of the 
mutations were found in COSMIC and reported in other lung cancer studies (Fouquet et 
al., 2004; Liu et al., 2002; Mori et al., 2004; Pelosi et al., 2012; The Cancer Genome 
Atlas, 2012).  One of the mutations (G266E) is a loss-of-function mutation (Alsner et al., 
2000; Fernandez-Cuesta et al., 2012; Pfaff et al., 2010), while the other mutation 
(G199V) is an anti-apoptotic gain-of-function mutation that promotes cell survival 
through the signal transducer and activator of transcription-3 (STAT3) pathway (Kim et 
al., 2009).  Knockdown experiments of G199V p53 mutants demonstrated a level of 
anti-tumor activity similar to high doses of chemotherapeutic agents, suggesting that 
inhibition of G199V p53 mutants may be beneficial for cancer treatment (Kim et al., 
2009). 
 
Gene Mutation DNA VAF RNA VAF 
TP53 G266E 1/7 (13%) 6/10 (60%) 
TP53 G199V 4/64 (6%) 8/57 (14%) 
STK11 W239* 1/13 (7%) 20/40 (50%) 
CDKN2A R131H 3/45 (7%) 22/62 (35%) 
CDKN2A R122*/R163* 2/16 (13%) 31/34 (91%) 
Table 4.  RNA Rescue mutations in lung adenocarcinoma that were below the detection threshold 
for other mutation callers used by the TCGA network working group.  The ratio of reads supporting 
the calls along with the variant allele frequencies are shown for both the DNA and RNA. 
 
Additionally, we found mutations in other well-known tumor suppressor genes such as 
STK11 and CDKN2A.  In the Lung Adenocarcinoma manuscript from TCGA, mutations 
in STK11 and CDKN2A were reported in 17% and 4% of all patients, respectively 
(submitted).  STK11 was the fourth most mutated gene and CDKN2A was the sixteenth 
(submitted). The proximal-proliferative subtype in Lung Adenocarinoma is characterized 
by an enrichment of mutations in KRAS along with inactivation mutations in STK11 
(submitted).  In the STK11 gene, we discovered a nonsense mutation at W239* in the 
structurally conserved protein kinase domain that was below the detection threshold for 
other mutation algorithms used by the network.  This mutation introduces an early stop 
codon in exon 5 (of 10) leading to a truncated protein.  This site is in COSMIC and was 
previously reported to be part of a 398 nucleotide deletion in a lung cancer study 
(Davies et al., 2005).  
 
In the CDKN2A gene, we found one nonsense mutation at R122*, R163* and one 
missense mutation at R131H, R80H that were both found in COSMIC.  CDKN2A is 
silenced in many CpG island methylator phenotype-high (CIMP-High) tumors by DNA 
methylation (submitted), but mutations and deletions in CDKN2A also result in loss of 
function.  The nonsense mutation at R122*, R163* results in an early stop codon in 
exon 2 (of 3-4, isoform dependent) leading to a truncated protein.  Previous lung cancer 
studies (Andujar et al., 2010; Blons et al., 2008; Imielinski et al., 2012) have reported 
frameshifts and deletions at this site.  The missense mutation at R131H was also found 
in colon cancer (The Cancer Genome Atlas, 2012), clear cell sarcoma (Takahira et al., 
2004), and chronic myeloid leukemia (Nagy et al., 2003) and confirmed as somatic in 
biliary tract cancer (Ueki et al., 2004). 
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The identification of somatic mutations is a key step in characterizing the cancer 
genome.  Until now, mutation calling algorithms have concentrated on comparing just 
the normal and tumor genomes within the same individual.  In the past few years, it has 
become common to also sequence the tumor transcriptome using RNA-Seq 
technologies.  We have developed a new method called RADIA that combines the 
normal DNA, tumor DNA, and tumor RNA from the same individual to increase the 
power to detect somatic mutations. 
 
The accurate detection of somatic mutations is complicated by biological and technical 
artifacts such as tumor purity and subclonality, varying allele frequencies, sequencing 
depths, and copy-number variation.  There is a trade-off between high sensitivity and 
high specificity, such that it is difficult to achieve both.  By including an additional 
dataset, we are increasing our ability to reliably detect mutations, especially at low 
variant allele frequencies (Supplementary Figure 7) where the signal to noise ratio 
becomes unfavorable.  By combining the three datasets, we are also able to confirm the 
expression of a mutation, providing more clues to its likely functional effect.  Confirming 
mutations through RNA-Seq is also advantageous for large genomic studies such as 
TCGA in providing a means for weak validation for mutation calls without costly 
resequencing for validation (Supplementary Figure 8).  We showed here that over 99% 
of the mutations with both strong DNA and RNA support validated in endometrial 
cancer, suggesting that if one is not using calls in clinical practice but rather estimating 
overall frequencies of specific mutations in a research cohort, the extreme expense in 
validating every call may not be warranted.  
 
With RADIA, we are able to detect mutations in important cancer genes such as TP53 
that were previously not identified by other algorithms because the signal was lost in the 
noise.  Somatic mutations are commonly used to group patients into subtypes that are 
critical for diagnosis and treatment of the disease.  Our ability to rescue back calls for 
individual patients will assist in correctly identifying each patientʼs specific subtype and 
consequently their treatment options. 
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Supplementary Figure 1:  Schematic of calls made by the DOM and TBM.  In the first 
and middle columns, there is enough DNA read support for the DOM method and other 
algorithms acting on DNA pairs to make a call.  In the middle and last columns, there is 
enough RNA read support for the TBM to make a call.  The middle column illustrates 
“RNA Confirmation” calls that are detected by both the DOM and the TBM due to high 
read support in both the DNA and RNA.  The last column represents the “RNA Rescue” 
calls that have some support in the DNA and strong evidence in the RNA.
Cancer Type Sample
Count
Total
Somatic 
SNVs
DNA
Only
Method
Triple 
BAM 
Method
RNA 
Rescue 
Calls
RNA 
Rescue 
Percent
Endometrial 177 27900 27390 6325 510 2%
Lung 
Adenocarcinoma
263 85044 79347 21484 5697 7%
Kidney Chromophobe 66 4163 3957 1042 206 5%
Thyroid 430 20849 19836 2882 1013 5%
Melanoma 347 584431 573925 70091 10498 2%
Low-Grade Glioma 289 13852 12837 3926 1015 4%
Prostate 314 14630 12653 4631 846 6%
Supplementary Table 1:  Summary of TCGA samples analyzed.  RADIA has been run 
on nearly 1,900 TCGA patients across seven different cancer types.  The RNA Rescue 
calls make up 2-7% of the total somatic mutation calls across the seven types of cancer.
Supplementary Figure 2:  Diagram of bamsurgeon methodology.  Mutations are spiked 
into BAM files by selecting locations with adequate coverage and changing a number of 
the bases according to the desirable variant allele frequency distribution.  Once the 
bases in the reads are changed, they are remapped to the genome, replacing the reads 
in the original BAM file.
Supplementary Figure 3:  Filters applied in the bamsurgeon simulation experiment 
where the DNA variant allele frequencies were distributed from 1-50% and the RNA was 
held constant at 25%.  Most of the DOM calls were filtered because of the low variant 
allele frequency and tumor strand bias.  In the TBM, most of the calls were filtered due 
to the minimum number of alternative alleles required to make a call (n=4) and strand 
bias in the tumor DNA and RNA.
Supplementary Figure 4:  Filters applied in the bamsurgeon simulation experiment 
where the RNA variant allele frequencies were distributed from 1-50% and the DNA was 
10% or less.  Most of the DOM calls were filtered because of the low DNA variant allele 
frequency and tumor strand bias.  In the TBM, most of the calls were filtered due to the 
minimum number of alternative alleles required to make a call (n=4) and the low RNA 
variant allele frequency. 
Supplementary Figure 5:  The distribution of the overlaps between RADIA and the 
validated MAF calls.  
Supplementary Figure 6:  Filters applied to the RADIA calls that validated as somatic in 
the MAF.  33% of the calls had a DNA VAF of 8% or less while 23% landed in blacklist 
regions that we didnʼt consider.
Supplementary Figure 7:  RNA Rescue calls are primarily found at low DNA variant 
allele frequencies, but they are also able to rescue back calls at higher frequencies that 
were filtered due to non-depth related artifacts (e.g. strand-bias).
Supplementary Figure 8:  The total number of mutations that are covered by at least 
one RNA read (yellow), one RNA read supporting the mutant allele (orange), and RNA 
Confirmation calls with high support in both the DNA and RNA (purple).
